Core Insights - Perspective Therapeutics, Inc. has initiated a Phase 1/2a dose-finding trial for its radiopharmaceutical [Pb]PSV359, targeting solid tumors expressing fibroblast activation protein alpha (FAP-α) [1][4] - The trial aims to assess the safety and preliminary anti-tumor activity of [Pb]PSV359, with patient selection based on SPECT imaging [1][4] - The company emphasizes the innovative design of [Pb]PSV359, which is optimized for preferential uptake in tumors and rapid clearance from healthy tissues [2][3] Company Overview - Perspective Therapeutics is focused on developing advanced radiopharmaceutical treatments for various cancers, utilizing alpha-emitting isotopes to deliver targeted radiation to cancer cells [6] - The company is also working on complementary imaging diagnostics to personalize treatment and improve patient outcomes through a "theranostic" approach [6] - Current clinical programs include treatments for melanoma, neuroendocrine tumors, and solid tumors, all in Phase 1/2a trials [7] FAP-α Significance - FAP-α is a protein commonly expressed in the tumor microenvironment of many epithelial cancers, and its higher expression is associated with poor prognosis in several solid tumors [5] - The targeting of FAP-α by [Pb]PSV359 aims to provide new treatment options for patients with advanced solid tumors [3][5]